Drug-Eluting Stents

Cardiology Clinics

Volumn 24, Issue 2, 2006, Pages 217-231

  Popma, Jeffrey J ^a   Tulli, Mark ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLIMUS A 9; DACTINOMYCIN; EVEROLIMUS; METHACRYLIC ACID DERIVATIVE; PACLITAXEL; POLYETHYLENE DERIVATIVE; POLYMER; RAPAMYCIN; RAPAMYCIN DERIVATIVE; STAINLESS STEEL; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ANEURYSM; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL DIAMETER; CANADA; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RELEASE; EUROPE; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; SLOW DRUG RELEASE; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-BACTERIAL AGENTS; CORONARY DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROSTHESIS DESIGN; STENTS;

EID: 33744981831     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2006.04.001     Document Type: Review

References (107)

1. Altmann D.B., Racz M., Battleman D.S., et al. Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients. Am Heart J 132 3 (1996) 503-507
2. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331 8 (1994) 489-495
3. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331 8 (1994) 496-501
4. Baim D., Cutlip D., Midei M., et al. Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol 87 2 (2001) 157-162
5. Heuser R., Lopez A., Kuntz R., et al. SMART: The microstent's ability to limit restenosis trial. Catheter Cardiovasc Interv 52 3 (2001) 269-277 [discussion 278]
6. Baim D., Cutlip D., O'Shaughnessy C., et al. Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol 87 2 (2001) 152-156
7. Cutlip D., Chauhan M., Baim D., et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 40 12 (2002) 2082-2089
8. Moses J., Leon M., Popma J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 14 (2003) 1315-1323
9. Sousa J., Costa M., Abizaid A., et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104 17 (2001) 2007-2011
10. Degertekin M., Serruys P., Tanabe K., et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation 108 22 (2003) 2747-2750
11. Sousa J., Costa M., Abizaid A., et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 111 18 (2005) 2326-2329
12. Sousa J.E., Costa M.A., Abizaid A., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103 2 (2001) 192-195
13. Sousa J., Costa M., Sousa A., et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 107 3 (2003) 381-383
14. Morice M., Serruys P., Sousa J., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 23 (2002) 1773-1780
15. Regar E., Serruys P., Bode C., et al. Angiographic findings of the multi-center Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106 15 (2002) 1949-1956
16. Tanabe K., Serruys P., Degertekin M., et al. Fate of side branches after coronary arterial sirolimus-eluting stent implantation. Am J Cardiol 90 9 (2002) 937-941
17. Serruys P., Degertekin M., Tanabe K., et al. Intravascular ultrasound findings in the multi-center, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 106 7 (2002) 798-803
18. Fajadet J., Morice M., Bode C., et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111 8 (2005) 1040-1044
19. Holmes D., Leon M., Moses J., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 5 (2004) 634-640
20. Popma J., Leon M., Moses J., et al. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 110 25 (2004) 3773-3780
21. Schofer J., Schluter M., Gershlick A., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 9390 (2003) 1093-1099
22. Schampaert E., Cohen E., Schluter M., et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43 6 (2004) 1110-1115
23. Sousa J., Costa M., Abizaid A., et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 107 1 (2003) 24-27
24. Airoldi F., Rogacka R., Briguori C., et al. Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. Am J Cardiol 94 10 (2004) 1297-1300
25. Saia F., Lemos P., Hoye A., et al. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 62 3 (2004) 283-288
26. Degertekin M., Regar E., Tanabe K., et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clinical experience. J Am Coll Cardiol 41 2 (2003) 184-189
27. Holmes D., Popma J., Kuntz R., et al. A multi-center, randomized study of the sirolimus-eluting Bx velocity stent versus intravascular brachytherapy in the treatment of patients with in-stent restenosis in native coronary arteries. Late-breaking clinical trials (2005), American Heart Association, Dallas (TX)
28. Lemos P., Lee C., Degertekin M., et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 41 11 (2003) 2093-2099
29. Lemos P., Saia F., Hofma S., et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 43 4 (2004) 704-708
30. Moussa I., Leon M., Baim D., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 19 (2004) 2273-2278
31. Ardissino D., Cavallini C., Bramucci E., et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292 22 (2004) 2727-2734
32. Hoye A., Tanabe K., Lemos P., et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 43 11 (2004) 1954-1958
33. Hoye A., Lemos P., Arampatzis C., et al. Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery. Coron Artery Dis 15 3 (2004) 171-175
34. Price M., Sawhney N., Kao J., et al. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 65 2 (2005) 208-211
35. Valgimigli M., van M.C., Ong A., et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 111 11 (2005) 1383-1389
36. Park S., Kim Y., Lee B., et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 45 3 (2005) 351-356
37. Aoki J., Hoye A., Staferov A., et al. Sirolimus-eluting stent implantation for chronic total occlusion of the left main coronary artery. J Interv Cardiol 18 1 (2005) 65-69
38. Arampatzis C., Lemos P., Tanabe K., et al. Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol 92 3 (2003) 327-329
39. Daemen J., Lemos P., and Serruys P. Multi-lesion culotte and crush bifurcation stenting with sirolimus-eluting stents: long-term angiographic outcome. J Invasive Cardiol 15 11 (2003) 653-656
40. Colombo A., Moses J., Morice M., et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 109 10 (2004) 1244-1249
41. Rizik D., Dowler D., and Villegas B. Balloon alignment T-stenting for bifurcation coronary artery disease using the sirolimus-eluting stent. J Invasive Cardiol 17 8 (2005) 437-439
42. Iakovou I., Sangiorgi G., Stankovic G., et al. Results and follow-up after implantation of four or more sirolimus-eluting stents in the same patient. Catheter Cardiovasc Interv 64 4 (2005) 436-439 [discussion 440-1]
43. Schluter M., Schofer J., Gershlick A., et al. Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent: a post hoc subanalysis of the pooled E- and C-SIRIUS trials. J Am Coll Cardiol 45 1 (2005) 10-13
44. Stone G., Ellis S., Cox D., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 3 (2004) 221-231
45. Grube E., Silber S., Hauptmann K., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 1 (2003) 38-42
46. Grube E., Silber S., Hauptmann K., et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol 96 1 (2005) 79-82
47. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based Paclitaxel-eluting stents for coronary artery lesions. Circulation 108 7 (2003) 788-794
48. Serruys P., Degertekin M., Tanabe K., et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 109 5 (2004) 627-633
49. Tanabe K., Serruys P., Grube E., et al. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107 4 (2003) 559-564
50. Stone G., Ellis S., Cox D., et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 16 (2004) 1942-1947
51. Cheneau E., Pichard A., Satler L., et al. Intravascular ultrasound stent area of sirolimus-eluting stents and its impact on late outcome. Am J Cardiol 95 10 (2005) 1240-1242
52. Stone G., Ellis S., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 10 (2005) 1215-1223
53. Dawkins K., Grube E., Guagliumi G., et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multi-center, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112 21 (2005) 3306-3313
54. Hermiller J., Raizner A., Cannon L., et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45 8 (2005) 1172-1179
55. Lansky A., Costa R., Mooney M., et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 45 8 (2005) 1180-1185
56. Moses J., Mehran R., Nikolsky E., et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 8 (2005) 1165-1171
57. Valgimigli M., Percoco G., Cicchitelli G., et al. High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study-protocol design and demography of the first 100 patients. Cardiovasc Drugs Ther 18 3 (2004) 225-230
58. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 17 (2005) 2109-2117
59. Tsuchida K., Ong A., Aoki J., et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 96 3 (2005) 395-398
60. Dangas G., Ellis S., Shlofmitz R., et al. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol 45 8 (2005) 1186-1192
61. Applegate R., Draughn T., and Davis B. Treatment of complex LAD-diagonal bifurcation disease using paclitaxel drug-eluting stents. J Invasive Cardiol 17 7 (2005) 390-392
62. Buellesfeld L., Gerckens U., Mueller R., et al. Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: Results of a Taxus CTO registry. Catheter Cardiovasc Interv 66 2 (2005) 173-177
63. Silber S., Hamburger J., Grube E., et al. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II. Herz 29 2 (2004) 171-180
64. Morice M., Colombo A., Meier B., et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 8 (2006) 895-904
65. Ellis S., Popma J., Lasala J., et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 8 (2005) 1193-1200
66. Windecker S., Remondino A., Eberli F., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 7 (2005) 653-662
67. Goy J., Stauffer J., Siegenthaler M., et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 45 2 (2005) 308-311
68. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 2 (2005) 165-171
69. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 7 (2005) 819-825
70. Meredith I., Ormiston J., Whitbourn R., et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. Eurointervention 1 (2005) 157-164
71. Collingwood R., Gibson L., Sedlik S., et al. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. Catheter Cardiovasc Interv 65 2 (2005) 227-232
72. American College of Cardiology, late breaking clinical trials, March 2005.
73. Serruys P., Sianos G., Abizaid A., et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46 2 (2005) 253-260
74. Tsuchida K., Piek J., Neumann F.J., et al. One-year results of a durable polymer everolimus-eluting stents in de novo coronary narrowings (The SPIRIT FIRST Trial). Eurointervention (2006) in press
75. Costa M., Angiolillo D., Teirstein P., et al. Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry. J Invasive Cardiol 17 8 (2005) 396-398
76. Serruys P., Ormiston J., Sianos G., et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol 44 7 (2004) 1363-1367
77. Hong M., Mintz G., Lee C., et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 107 4 (2003) 517-520
78. Park S., Shim W., Ho D., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348 16 (2003) 1537-1545
79. Gershlick A., De Scheerder I., Chevalier B., et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109 4 (2004) 487-493
80. Lansky A., Costa R., Mintz G., et al. Nonpolymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 109 16 (2004) 1948-1954
81. de la Fuente L., Miano J., Mrad J., et al. Initial results of the Quanam drug-eluting stent (QuaDS-QP-2) Registry (BARDDS) in human subjects. Catheter Cardiovasc Interv 53 4 (2001) 480-488
82. Grube E., Lansky A., Hauptmann K., et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 44 7 (2004) 1368-1372
83. Liistro F., Stankovic G., Di M.C., et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105 16 (2002) 1883-1886
84. Virmani R., Liistro F., Stankovic G., et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 21 (2002) 2649-2651
85. Bavry A., Kumbhani D., Helton T., et al. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 45 6 (2005) 941-946
86. Ong A., Hoye A., Aoki J., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 6 (2005) 947-953
87. Katritsis D., Karvouni E., and Ioannidis J. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 95 5 (2005) 640-643
88. Jeremias A., Sylvia B., Bridges J., et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109 16 (2004) 1930-1932
89. Kerner A., Gruberg L., Kapeliovich M., et al. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv 60 4 (2003) 505-508
90. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 17 (2005) 2126-2130
91. Ong A., McFadden E., Regar E., et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 12 (2005) 2088-2092
92. Kang W., Han S., Choi K., et al. Acute myocardial infarction caused by late stent thrombosis after deployment of a paclitaxel-eluting stent. J Invasive Cardiol 17 7 (2005) 378-380
93. Lee C., Tan H., Ong H., et al. Late thrombotic occlusion of paclitaxel eluting stent more than one year after stent implantation. Heart 90 12 (2004) 1482
94. Drachman D., Edelman E., Seifert P., et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 36 7 (2000) 2325-2332
95. Carter A., Aggarwal M., Kopia G., et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63 4 (2004) 617-624
96. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 6 (2004) 701-705
97. Finn A., Kolodgie F., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 2 (2005) 270-278
98. Tanabe K., Serruys P., Degertekin M., et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation 111 7 (2005) 900-905
99. Fujii K., Mintz G., Kobayashi Y., et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 109 9 (2004) 1085-1088
100. Kereiakes D., Kuntz R., Mauri L., et al. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 45 8 (2005) 1206-1212
101. Takebayashi H., Kobayashi Y., Dangas G., et al. Restenosis due to underexpansion of sirolimus-eluting stent in a bifurcation lesion. Catheter Cardiovasc Interv 60 4 (2003) 496-499
102. Singh H., Singh C., Aggarwal N., et al. Mycotic aneurysm of left anterior descending artery after sirolimus-eluting stent implantation: a case report. Catheter Cardiovasc Interv 65 2 (2005) 282-285
103. Stabile E., Escolar E., Weigold G., et al. Marked malposition and aneurysm formation after sirolimus-eluting coronary stent implantation. Circulation 110 5 (2004) e47-e48
104. Vik-Mo H., Wiseth R., and Hegbom K. Coronary aneurysm after implantation of a paclitaxel-eluting stent. Scand Cardiovasc J 38 6 (2004) 349-352
105. Weintraub W. Economics of sirolimus-eluting stents: drug-eluting stents have really arrived. Circulation 110 5 (2004) 472-474
106. van Hout B., Serruys P., Lemos P., et al. One-year cost-effectiveness of sirolimus-eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 91 4 (2005) 507-512
107. Cohen D., Bakhai A., Shi C., et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 110 5 (2004) 508-514